HMGB1 is a compelling biomarker candidate, but it is not an easy one. It’s closely tied to inflammation, tissue damage, and disease progression, yet published results often vary widely across studies. In many cases, that variability is not just biological. It reflects a measurement problem. HMGB1 changes with redox state, interacts with other molecules in biological fluids, and is highly sensitive to pre-analytical handling. Assays that treat it like a simple soluble protein can miss important biology or produce inconsistent readouts. (Yang et al. PMC)
That is why HMGB1 studies rise or fall on assay strategy. The key question is not simply whether an antibody binds HMGB1. It is whether the reagent detects the relevant form of HMGB1 in the sample type, matrix, and assay format you are actually using.
Why HMGB1 Is So Difficult to Measure
HMGB1 operates in very different biological contexts. Inside the cell, it is a highly abundant non-histone chromatin protein that helps organize DNA and supports transcription, replication, repair, and genome stability. Outside the cell, it acts as a damage-associated molecular pattern, or DAMP, where its activity depends on how it was released, its oxidation state, and which partner molecules it encounters. (Štros et al. PMC)
That shift matters for detection. Intracellular HMGB1 in a denatured lysate is not the same analytical target as extracellular HMGB1 circulating in plasma, bound in complexes, or altered by oxidation. A reagent that performs well in Western blot may not behave the same way in native serum or plasma. For HMGB1, assay context is part of the biology.
Three Technical Factors That Complicate HMGB1 Measurement
1. Redox state changes what HMGB1 does - and what some assays detect
HMGB1 is not a single fixed analyte. Its three cysteines can exist in different redox states, and those states are linked to different extracellular activities. Fully reduced HMGB1 can form a complex with CXCL12 and promote chemotaxis through CXCR4. Disulfide HMGB1 is associated with cytokine-inducing activity through TLR4/MD-2. Terminally oxidized HMGB1 is generally considered functionally inactive in these inflammatory settings. (Yang et al. PMC)
From an assay standpoint, that means “HMGB1” is often a mixed population rather than a single molecular species. Antibodies may not recognize each form equally, and sample handling can shift redox balance before detection even begins. When researchers compare studies without accounting for these differences, they may be comparing different analyte pools rather than true biological disagreement. (Yang et al. PMC)
2. HMGB1 forms complexes in biological fluids that can mask detection
In plasma and serum, HMGB1 is highly interactive. It can associate with DNA, RNA, histones, nucleosomes, LPS, IL-1 family partners, haptoglobin, and endogenous antibodies. These interactions are not just biologically interesting - they can directly affect assay performance by masking epitopes or reducing antibody access. In ELISA-based workflows, endogenous IgG and IgM have been specifically reported as sources of interference, and dissociation or extraction steps can materially change the measured signal. (Yang et al. PMC)
This is one reason matrix matters so much for HMGB1. An assay may perform cleanly with recombinant protein in buffer but behave very differently in septic plasma, autoimmune samples, or oncology specimens with high levels of cell-free chromatin and inflammatory mediators. For HMGB1, matrix effect is often part of the assay challenge, not background noise around it.
3. Pre-analytical variables can distort results before the assay starts
HMGB1 measurement is unusually sensitive to how samples are collected and processed. Serum and plasma are not interchangeable here - published work shows serum HMGB1 can read higher than plasma because clotting itself releases HMGB1. Hemolytic samples are also problematic, and repeated freeze-thaw cycles should be avoided. Storage conditions, aliquoting strategy, and the choice of anticoagulant can all influence what eventually gets measured. (Štros et al. PMC)
For biomarker studies, that means reproducibility depends on workflow discipline as much as assay chemistry. If collection and handling are not standardized, even a well-designed detection reagent may produce noisy or misleading data.
What to Look for in HMGB1 Detection Reagents
For HMGB1, application-specific validation matters more than broad marketing labels. A reagent validated for Western blot has demonstrated performance on denatured protein, but that does not guarantee equivalent performance in native serum, plasma, or a sandwich immunoassay. (Štros et al. PMC)
For extracellular HMGB1 work, priority should go to reagents with evidence in the relevant matrix and assay format. Spike-and-recovery, dilution linearity, and pair performance in real biological samples are more informative than buffer-only data. When the study depends on distinguishing broad HMGB1 detection from a narrower molecular subset, epitope choice and antibody format also become more important. Monoclonals can support tighter specificity and lot consistency, while broader-coverage reagents may help when the target exists in multiple forms or contexts.
For sandwich assays, matched-pair performance is critical. The question is not only whether each antibody binds HMGB1, but whether the capture and detection reagents can recognize accessible, non-overlapping epitopes under real sample conditions.
Practical Strategies for More Reproducible HMGB1 Data
The right method depends on the biological question. Western blotting and immunostaining can be useful for intracellular localization and expression studies. ELISA and related immunoassays are often better suited to extracellular quantitation in plasma, serum, or culture supernatants. When redox-specific interpretation is central to the claim, orthogonal methods may be needed to strengthen confidence in what form is actually being measured. (Štros et al. PMC)
Just as important, standardize the workflow around the assay. Define serum versus plasma upfront. Keep collection tubes, processing times, storage conditions, and freeze-thaw history consistent across cohorts. Build in spike-and-recovery or dilution-linearity checks when working in complex matrices. For translational biomarker work, these steps are often the difference between a promising signal and a reproducible one.
Choosing Tools That Match the Biology
HMGB1 is a good example of why biomarker measurement starts with assay fit, not just target selection. Researchers need tools that match the biology of the analyte and the realities of the matrix. That means thinking beyond simple target recognition and asking a more useful question: can this reagent support reproducible measurement in the context that matters to the study?
At Aviva, that is the lens we apply to antibody selection and assay support. For challenging targets like HMGB1, application-specific validation, matrix-aware performance, and fit-for-purpose assay design matter more than a generic claim of reactivity. Whether the goal is intracellular characterization or extracellular biomarker measurement, the strongest workflows are built around the form of the analyte you actually need to detect.
1. Yang H, Wang H, Andersson U. Targeting Inflammation Driven by HMGB1. Front Immunol. 2020 Mar 20;11:484. doi: 10.3389/fimmu.2020.00484. PMID: 32265930; PMCID: PMC7099994.
2. Štros M, Polanská EV, Hlaváčová T, Skládal P. Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19. Biomolecules. 2022 Apr 5;12(4):544. doi: 10.3390/biom12040544. PMID: 35454134; PMCID: PMC9031208.
As discussed, HMGB1 studies often require different tools depending on whether the goal is intracellular characterization, tissue localization, or quantitative measurement in biological fluids. Aviva offers a variety of HMGB1 reagents for human and mouse workflows, including recombinant and polyclonal antibodies plus sandwich ELISA kits.